AbbVie Inc. $ABBV Shares Purchased by MAI Capital Management

MAI Capital Management boosted its position in AbbVie Inc. (NYSE:ABBV) by 1.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 546,284 shares of the company’s stock after purchasing an additional 6,850 shares during the quarter. AbbVie comprises approximately 0.8% of MAI Capital Management’s investment portfolio, making the stock its 27th largest position. MAI Capital Management’s holdings in AbbVie were worth $126,487,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Norges Bank acquired a new position in AbbVie during the second quarter worth $4,288,200,000. Laurel Wealth Advisors LLC increased its position in shares of AbbVie by 18,384.4% during the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after acquiring an additional 5,675,095 shares during the period. Vanguard Group Inc. boosted its stake in shares of AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after buying an additional 3,380,842 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of AbbVie by 169.3% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock valued at $876,662,000 after purchasing an additional 2,969,202 shares during the last quarter. Finally, Raymond James Financial Inc. raised its holdings in shares of AbbVie by 41.8% in the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Announced a $380 million investment to build two new active pharmaceutical ingredient (API) plants at its North Chicago campus to support next‑generation neuroscience and obesity medicines; construction starts spring 2026 and facilities are expected online by 2029 — boosts capacity, onshoring and long‑term production control. AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States
• Positive Sentiment: FDA approved the VENCLEXTA (venetoclax) + acalabrutinib combination as a first‑line, all‑oral fixed‑duration regimen for previously untreated CLL — a label expansion that can meaningfully enlarge addressable market and near‑term revenue potential. FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL
• Positive Sentiment: Barclays initiated coverage with an Overweight rating and $275 price target, calling out upside from operating‑leverage and growth potential — an influential analyst endorsement that may support the stock. Barclays Initiates AbbVie (ABBV) with Overweight Rating on Growth Potential
• Positive Sentiment: Coverage pieces highlighting AbbVie’s high dividend yield and steady payout profile continue to attract income investors, supporting demand for the shares from yield‑focused buyers. This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income
• Neutral Sentiment: Company to present at the TD Cowen Healthcare Conference on March 3 — standard investor access that offers a near‑term catalyst for management commentary but no immediate guarantee of new guidance. AbbVie to Present at the TD Cowen 46th Annual Health Care Conference
• Neutral Sentiment: AbbVie completed a real‑world study of Vraylar in Bipolar I disorder — a data milestone that reduces uncertainty around real‑world use but is unlikely to move revenue materially in the near term. AbbVie’s Real‑World Vraylar Study in Bipolar I Disorder Reaches Completion
• Neutral Sentiment: Early‑stage progress: AbbVie launched a Phase 1 trial for ABBV‑8736 to compare injection routes — positive for pipeline momentum but inherently early and higher risk. AbbVie Advances ABBV-8736 With New Trial Comparing Injection Routes
• Neutral Sentiment: Coverage and fair‑value tweaks from some outlets modestly lifted model targets (small upward adjustments) — indicates analysts are refining views rather than issuing large directional revisions. How Pipeline Shifts And Competition Are Reshaping The AbbVie (ABBV) Investment Narrative
• Negative Sentiment: Analysts and articles flag increasing competition (and lingering execution risk) in immunology and other franchises; that pressure, plus the need to replace legacy revenue over time, is a structural headwind for multiples. Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
• Negative Sentiment: Big capex spend has long‑term benefits but increases near‑term cash deployment; investors concerned about execution/timing (projects complete by 2029) may be cautious in the near term. AbbVie to invest $380 million to expand US manufacturing in Illinois

AbbVie Trading Down 0.5%

Shares of ABBV stock opened at $228.44 on Wednesday. The company has a market cap of $403.92 billion, a PE ratio of 96.80, a P/E/G ratio of 0.80 and a beta of 0.35. The company’s fifty day simple moving average is $224.17 and its 200-day simple moving average is $222.67. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s payout ratio is 293.22%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Royal Bank Of Canada set a $260.00 price target on shares of AbbVie and gave the company an “outperform” rating in a research report on Tuesday. Citigroup dropped their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and upped their target price for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Scotiabank initiated coverage on shares of AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price target on the stock. Finally, Piper Sandler boosted their price target on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.